E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice
-
By
-
Richard G. Hoover
-
Emily C. Matchett
-
Jacki Kornbluth
-
July 15, 2026
Clinical Scorecard: E3 Ubiquitin Ligase NKLAM/RNF19b Inhibits Myc-Induced B Cell Lymphoma Development in Eμ-myc Mouse Model
At a Glance
| Category | Detail |
|---|
| Condition | B Cell Lymphoma |
| Key Mechanisms | NKLAM regulates myc and Bcl-2 expression in B cell progenitors, influencing lymphomagenesis. |
| Target Population | Eμ-myc transgenic mice |
| Care Setting | Animal research model |
Key Highlights
- NKLAM deficiency accelerates myc-driven B cell lymphomagenesis.
- NKLAM limits expression of myc and Bcl-2 in non-neoplastic B cell progenitors.
- Infusion of NKLAM+ immune cells extends survival in NKLAM-deficient Eμ-myc mice.
Guideline-Based Recommendations
Diagnosis
- Monitor for development of B cell lymphomas in Eμ-myc mice.
Management
- Consider NKLAM's role in tumor development when evaluating treatment strategies.
Monitoring & Follow-up
- Assess levels of precursor B cells and lymphoma phenotype in NKLAM KO mice.
Risks
- Increased tumor development and altered lymphoma characteristics in NKLAM-deficient models.
Patient & Prescribing Data
N/A (animal model study)
NKLAM+ immune cell infusion may influence lymphoma aggressiveness.
Clinical Best Practices
- Utilize Eμ-myc mouse model for studying B cell lymphomagenesis.
- Investigate NKLAM's role in immune response and tumor development.
Related Resources & Content
